UNIGE document Scientific Article - Review
previous document  unige:118033  next document
add to browser collection
Title

Safety of Symptomatic Slow-Acting Drugs for Osteoarthritis: Outcomes of a Systematic Review and Meta-Analysis

Authors
Honvo, Germain
Reginster, Jean-Yves
Rabenda, Véronique
Geerinck, Anton
Mkinsi, Ouafa
Charles, Alexia
Cooper, Cyrus
show hidden authors show all authors [1 - 10]
Published in Drugs & Aging. 2019, vol. 36, no. Suppl.1, p. S65-S99
Abstract BACKGROUND: Symptomatic slow-acting drugs for osteoarthritis (SYSADOAs) are an important drug class in the treatment armamentarium for osteoarthritis (OA). OBJECTIVE: We aimed to re-assess the safety of various SYSADOAs in a comprehensive meta-analysis of randomized placebo-controlled trials, using, as much as possible, data from full safety reports. METHODS: We performed a systematic review and random-effects meta-analyses of randomized, double-blind, placebo-controlled trials that assessed adverse events (AEs) with various SYSADOAs in patients with OA. The databases MEDLINE, Cochrane Central Register of Controlled Trials (Ovid CENTRAL) and Scopus were searched. The primary outcomes were overall severe and serious AEs, as well as AEs involving the following Medical Dictionary for Regulatory Activities (MedDRA) system organ classes (SOCs): gastrointestinal, cardiac, vascular, nervous system, skin and subcutaneous tissue, musculoskeletal and connective tissue, renal and urinary system.
Identifiers
PMID: 31073924
Full text
Structures
Research group Génétique des ostéoporoses (544)
Citation
(ISO format)
HONVO, Germain et al. Safety of Symptomatic Slow-Acting Drugs for Osteoarthritis: Outcomes of a Systematic Review and Meta-Analysis. In: Drugs & Aging, 2019, vol. 36, n° Suppl.1, p. S65-S99. https://archive-ouverte.unige.ch/unige:118033

34 hits

28 downloads

Update

Deposited on : 2019-05-22

Export document
Format :
Citation style :